Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Rallybio's enterprise value was -$8.95M on Nov 11, 2026, against -$32.00M a year earlier. Over the last 5 years it ranged from -$70.37M to $317.54M, with a median of -$8.95M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$8.95M | – |
| 2025 | Dec 31, 2025 | -$30.53M | – |
| 2024 | Dec 31, 2024 | -$35.27M | – |
| 2023 | Dec 29, 2023 | -$31.06M | -139.6% |
| 2022 | Dec 30, 2022 | $78.44M | -34.4% |
| 2021 | Dec 31, 2021 | $119.54M | – |
See a number that looks wrong?